Fig. 3From: Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate testsImpact of HER2 testing. a Missed gain in life expectancy; b avoidable recurrences and progressions; and c QALYs missed in patients with early and metastatic breast cancer based on US patient numbers and NordiQC FN and FP results; weighted according to the estimated prevalence of IHC 2+ cases (20 %). EBC, early breast cancer; FN, false negative; FP, false positive; IHC, immunohistochemistry; IVD, in vitro diagnostic; MBC, metastatic breast cancer; QALY, quality-adjusted life-yearBack to article page